Skip to content

Virtual Reality and Spinal Stimulation to Improve Arm Function

Immersive Virtual Reality and Noninvasive Spinal Stimulation to Promote Arm Function in Individuals With Tetraplegia

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05065437
Enrollment
0
Registered
2021-10-04
Start date
2022-06-30
Completion date
2024-01-01
Last updated
2022-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tetraplegia

Keywords

upper limb function, virtual reality, spinal cord stimulation

Brief summary

The main objective of our work is to develop and test the safety and feasibility of a home-based upper limb rehabilitation program for individuals with tetraplegia. The program will consist of simultaneous non-invasive spinal cord stimulation and immersive virtual exercises of the upper limbs, with a focus on shoulder and elbow function.

Interventions

OTHERActive (Virtual reality and spinal stimulation)

Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. incomplete low tetraplegia (C5-8; \[ASIA\] classification B-D), 2. free of contraindications to transspinal stimulation, 3. more than one-year post-injury, 4. stable medication regimen for the past month, 5. utilization of wheelchair as a primary mode of mobility (\>75% of the time). -

Exclusion criteria

1. Neurologic injury other than spinal cord injury 2. severe medical illness.

Design outcomes

Primary

MeasureTime frameDescription
Change in medical statusBaseline to post intervention, approximately 4 weeksSafety of the intervention will be assessed as the number of participants who experience a reduction in medical stability and/or functionality from before to after the intervention.
Acceptability of the treatmentPost intervention, approximately 4 weeksAcceptability of the treatment will be assessed using the Treatment Evaluation Inventory-Short Form. Items are scored using a 5-point scale, with 1 equaling strongly disagree and 5 equaling strongly agree. TEI-SF scores can range from 9 to 45, with higher scores representing greater acceptance of the treatment.
Usability of the treatmentPost intervention, approximately 4 weeksUsability of the treatment will be assessed using the Usefulness, Satisfaction, and Ease of Use (USE) Questionnaire. Items are rated on a seven-point scale ranging from strongly disagree to strongly agree. A higher scale score indicates higher usability.

Secondary

MeasureTime frameDescription
Change in affectBaseline to post intervention, approximately 4 weeksAffect will be assessed using the Positive and Negative Affect Schedule (PANAS). The PANAS is a 20-item measure that measures the intensity of 20 emotions on a 0-5 scale ranging from not at all to extremely.
Change in upper limb functionBaseline to post intervention, approximately 4 weeksUpper limb function will be assessed using the Spinal Cord Independence Measure (SCIM). The SCIM is composed of 19 items that assess function. SCIM scores range from 0 to 100.
Change in current pain intensityBaseline to post intervention, approximately 4 weeksCurrent pain intensity will be assessed using a Numeric Rating Scale (NRS). Participants will rate their current pain (multiple types of pain) on a 0-10 scale (0 = no pain and 10 = worst possible pain).
Change in clinical muscle strengthBaseline to post intervention, approximately 4 weeksClinical muscle strength will be assessed using the American Spinal Cord Injury Association (ASIA) Upper Extremity Motor Score. Motor strength is rated on a 6 point scale with higher ratings indicating greater strength.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026